Enlivex Therapeutics (NASDAQ:ENLV) Lowered to “Sell” Rating by Wall Street Zen

Enlivex Therapeutics (NASDAQ:ENLV) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

ENLV has been the subject of a number of other reports. D. Boral Capital reiterated a “hold” rating on shares of Enlivex Therapeutics in a report on Monday, November 24th. HC Wainwright increased their price target on shares of Enlivex Therapeutics from $7.00 to $13.00 and gave the company a “buy” rating in a report on Monday, January 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Enlivex Therapeutics in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Enlivex Therapeutics presently has an average rating of “Hold” and an average price target of $13.00.

Enlivex Therapeutics Price Performance

Shares of ENLV opened at $1.11 on Friday. The company has a market capitalization of $263.49 million, a PE ratio of -2.02 and a beta of 1.63. Enlivex Therapeutics has a one year low of $0.66 and a one year high of $2.10. The company’s fifty day moving average price is $0.95 and its 200 day moving average price is $1.06.

Enlivex Therapeutics (NASDAQ:ENLV) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.03. Analysts anticipate that Enlivex Therapeutics will post -0.7 earnings per share for the current year.

Institutional Investors Weigh In On Enlivex Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Jane Street Group LLC lifted its holdings in shares of Enlivex Therapeutics by 244.1% during the 4th quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock worth $52,000 after acquiring an additional 52,553 shares during the period. Susquehanna International Group LLP acquired a new position in Enlivex Therapeutics in the third quarter worth about $57,000. HRT Financial LP lifted its stake in Enlivex Therapeutics by 719.4% during the fourth quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after purchasing an additional 135,198 shares during the period. Renaissance Technologies LLC lifted its stake in Enlivex Therapeutics by 99.4% during the fourth quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock worth $221,000 after purchasing an additional 156,336 shares during the period. Finally, Citizens Financial Group Inc. RI acquired a new stake in Enlivex Therapeutics during the third quarter valued at approximately $241,000. Institutional investors and hedge funds own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.